TD Cowen Maintains Sagimet Biosciences(SGMT.US) With Buy Rating
TD Cowen analyst Ritu Baral maintains $Sagimet Biosciences(SGMT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.5% and a total average return of 7.4% over the p
Express News | Sagimet Biosciences To Host Conference Call And Webcast On June 13, 2024, To Discuss Positive Data From FASCINATE-2 Phase 2b Trial Of Denifanstat In MASH Patients Presented At EASL Congress
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data From ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
Sagimet Biosciences Price Target Maintained With a $48.00/Share by JMP Securities
Sagimet Biosciences Price Target Maintained With a $48.00/Share by JMP Securities
Express News | HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
What's Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences Inc (NASDAQ:SGMT) presented data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MA
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial
Sagimet Biosciences (SGMT) said Thursday that additional data from a phase 2b trial of denifanstat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, or MASH, showed t
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) edged up 0.03% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Thursday's premarket activity, as investors await t
Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance f
Express News | Sagimet Biosciences Presents Data From ITT and F3 Patient Population in Phase 2B Fascinate-2 Clinical Trial of Denifanstat at Easl International Liver Congress 2024
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower.At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE
Eli Lilly and Co (LLY.US) is too strong, NASH concept stocks suffer a painful blow.
According to the Zhitong Finance app, the stock prices of drug developers for non-alcoholic steatohepatitis (NASH), a type of liver disease, fell on Wednesday. The reason is that earlier detailed data from Eli Lilly and Co's (LLY.US) weight loss drug, Tirzepatide, showed its potential in treating NASH. The data shows that Madrigal Pharmaceuticals (MDGL.US) fell more than 13%. It is understood that earlier this year, the company received FDA approval for its main asset, Rezafungin, used for NASH (also known as metabolic dysfunction-associated fatty liver disease, MASH).
Eli Lilly Details NASH Effects of Weight Loss Drug
Piper Sandler Sticks to Its Buy Rating for Sagimet Biosciences, Inc. Class A (SGMT)
Buy Rating Justified: Sagimet Biosciences' Undervalued Market Position and Promising NASH Treatment Potential
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright analyst Ed Arce maintains $Sagimet Biosciences(SGMT.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 38.5% an
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $48
JMP Securities analyst Jonathan Wolleben maintains $Sagimet Biosciences(SGMT.US)$ with a buy rating, and maintains the target price at $48.According to TipRanks data, the analyst has a success rate of
Buy Rating Affirmed for Sagimet Biosciences on Promising NASH Treatment Potential
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Stifel cut
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibro
No Data